Test-retest analysis of a non-invasive method of quantifying [(11)C]-PBR28 binding in Alzheimer's disease - PubMed (original) (raw)
Test-retest analysis of a non-invasive method of quantifying [(11)C]-PBR28 binding in Alzheimer's disease
Akshay Nair et al. EJNMMI Res. 2016 Dec.
Erratum in
- Erratum to: Test-retest analysis of a non-invasive method of quantifying [(11)C]-PBR28 binding in Alzheimer's disease.
Nair A, Veronese M, Xu X, Curtis C, Turkheimer F, Howard R, Reeves S. Nair A, et al. EJNMMI Res. 2017 Dec;7(1):14. doi: 10.1186/s13550-017-0256-5. Epub 2017 Feb 14. EJNMMI Res. 2017. PMID: 28197899 Free PMC article. No abstract available.
Abstract
Purpose: In order to maximise the utility of [(11)C]-PBR28 for use in longitudinal studies and clinical trials in Alzheimer's disease (AD), there is a need to develop non-invasive metrics of tracer binding that do not require arterial cannulation. Recent work has suggested that standardised uptake value (SUV)-based methods may be sensitive to changes in translocator protein (TSPO) levels associated with neurodegeneration. However, the test-retest reliability of these approaches in AD over a time period relevant for clinical trials is unknown. In this study, the test-retest reliability of three SUV-based metrics was assessed in AD patients over 12 weeks.
Methods: Five patients with mild AD and the high-affinity binding TSPO genotype underwent two [(11)C]-PBR28 PET scans approximately 12 weeks apart. The test-retest reliability (TRR) of the unadjusted SUV, SUV relative to cerebellar grey matter (SUVRC) and SUV normalised to whole brain activity (SUVRWB) in nine cortical and limbic regions of interest was assessed using the absolute variability and the intraclass correlation coefficient.
Results: Of the three measures, SUVRWB performed best overall, showing low absolute variability (mean -0.13 %, SD 2.47 %) and high reliability (mean ICC = 0.83). Unadjusted SUV also performed well, with high reliability (ICC = 0.94) but also high variability (mean -1.24 %, SD 7.28 %). By comparison, the SUVRC showed higher variability (mean -3.98 %, SD 7.07 %) and low reliability (ICC = 0.65).
Conclusions: In this AD sample, we found that SUV-derived metrics of [(11)C]-PBR28 binding showed high stability over 12 weeks. These results compare favourably with studies reporting TRR of absolute quantification of [(11)C]-PBR28. Pending further validation of SUV-based measures of [(11)C]-PBR28, semi-quantitative methods of [(11)C]-PBR28 analysis may prove useful in longitudinal studies of AD.
Keywords: Alzheimer’s; Dementia; Inflammation; Microglia; Positron emission tomography.
Similar articles
- Comparison of standardized uptake values with volume of distribution for quantitation of [(11)C]PBR28 brain uptake.
Yoder KK, Territo PR, Hutchins GD, Hannestad J, Morris ED, Gallezot JD, Normandin MD, Cosgrove KP. Yoder KK, et al. Nucl Med Biol. 2015 Mar;42(3):305-8. doi: 10.1016/j.nucmedbio.2014.11.003. Epub 2014 Nov 15. Nucl Med Biol. 2015. PMID: 25487553 Free PMC article. - Positron Emission Tomography studies with [11C]PBR28 in the Healthy Rodent Brain: Validating SUV as an Outcome Measure of Neuroinflammation.
Tóth M, Doorduin J, Häggkvist J, Varrone A, Amini N, Halldin C, Gulyás B. Tóth M, et al. PLoS One. 2015 May 21;10(5):e0125917. doi: 10.1371/journal.pone.0125917. eCollection 2015. PLoS One. 2015. PMID: 25996996 Free PMC article. - In vivo radioligand binding to translocator protein correlates with severity of Alzheimer's disease.
Kreisl WC, Lyoo CH, McGwier M, Snow J, Jenko KJ, Kimura N, Corona W, Morse CL, Zoghbi SS, Pike VW, McMahon FJ, Turner RS, Innis RB; Biomarkers Consortium PET Radioligand Project Team. Kreisl WC, et al. Brain. 2013 Jul;136(Pt 7):2228-38. doi: 10.1093/brain/awt145. Epub 2013 Jun 17. Brain. 2013. PMID: 23775979 Free PMC article. - N-(6-[18F]Fluoro-4-phenoxypyridin-3-yl)-N-(2-methoxybenzyl)acetamide.
Chopra A. Chopra A. 2013 Mar 26 [updated 2013 Apr 25]. In: Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004–2013. 2013 Mar 26 [updated 2013 Apr 25]. In: Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004–2013. PMID: 23638491 Free Books & Documents. Review. - Recent developments on PET radiotracers for TSPO and their applications in neuroimaging.
Zhang L, Hu K, Shao T, Hou L, Zhang S, Ye W, Josephson L, Meyer JH, Zhang MR, Vasdev N, Wang J, Xu H, Wang L, Liang SH. Zhang L, et al. Acta Pharm Sin B. 2021 Feb;11(2):373-393. doi: 10.1016/j.apsb.2020.08.006. Epub 2020 Aug 25. Acta Pharm Sin B. 2021. PMID: 33643818 Free PMC article. Review.
Cited by
- In vivo PET imaging of neuroinflammation in Alzheimer's disease.
Lagarde J, Sarazin M, Bottlaender M. Lagarde J, et al. J Neural Transm (Vienna). 2018 May;125(5):847-867. doi: 10.1007/s00702-017-1731-x. Epub 2017 May 17. J Neural Transm (Vienna). 2018. PMID: 28516240 Review. - Tracers progress for positron emission tomography imaging of glial-related disease.
Jia H, Xie T. Jia H, et al. J Biomed Res. 2022 Jun 28;36(5):321-335. doi: 10.7555/JBR.36.20220017. J Biomed Res. 2022. PMID: 36131689 Free PMC article. - Brain microglia activation and peripheral adaptive immunity in Parkinson's disease: a multimodal PET study.
Liu SY, Qiao HW, Song TB, Liu XL, Yao YX, Zhao CS, Barret O, Xu SL, Cai YN, Tamagnan GD, Sossi V, Lu J, Chan P. Liu SY, et al. J Neuroinflammation. 2022 Aug 29;19(1):209. doi: 10.1186/s12974-022-02574-z. J Neuroinflammation. 2022. PMID: 36038917 Free PMC article. - TSPO-PET imaging using [18F]PBR06 is a potential translatable biomarker for treatment response in Huntington's disease: preclinical evidence with the p75NTR ligand LM11A-31.
Simmons DA, James ML, Belichenko NP, Semaan S, Condon C, Kuan J, Shuhendler AJ, Miao Z, Chin FT, Longo FM. Simmons DA, et al. Hum Mol Genet. 2018 Aug 15;27(16):2893-2912. doi: 10.1093/hmg/ddy202. Hum Mol Genet. 2018. PMID: 29860333 Free PMC article. - Clinical heterogeneity of neuro-inflammatory PET profiles in early Alzheimer's disease.
Gouilly D, Salabert AS, Bertrand E, Goubeaud M, Catala H, Germain J, Ainaoui N, Rafiq M, Benaiteau M, Carlier J, Nogueira L, Planton M, Hitzel A, Méligne D, Sarton B, Silva S, Lemesle B, Payoux P, Thalamas C, Péran P, Pariente J. Gouilly D, et al. Front Neurol. 2023 Jul 31;14:1189278. doi: 10.3389/fneur.2023.1189278. eCollection 2023. Front Neurol. 2023. PMID: 37588670 Free PMC article.
References
- Calsolaro V, Edison P. Neuroinflammation in Alzheimer's disease: Current evidence and future directions. Alzheimers Dement. 2016. doi:10.1016/j.jalz.2016.02.010 - PubMed
- Turkheimer FE, Edison P, Pavese N, Roncaroli F, Anderson AN, Hammers A, et al. Reference and target region modeling of [11C]-(R)-PK11195 brain studies. J Nucl Med. 2007;48(1):158–167. - PubMed
Grants and funding
- G0900891/MRC_/Medical Research Council/United Kingdom
- G1100809/MRC_/Medical Research Council/United Kingdom
- MC_U120085814/MRC_/Medical Research Council/United Kingdom
- NIHR/CS/010/019/DH_/Department of Health/United Kingdom
LinkOut - more resources
Full Text Sources
Other Literature Sources